Comparison of cytogenetic clonal evolution patterns following allogeneic hematopoietic transplantation versus conventional treatment in patients at relapse of AML

Biology of Blood and Marrow Transplantation

Volumn 16, Issue 12, 2010, Pages 1649-1657

  Bacher, Ulrike ^a   Haferlach, Torsten ^b   Alpermann, Tamara ^b   Zenger, Melanie ^b   Kröger, Nicolaus ^a   Beelen, Dietrich W ^c   Kern, Wolfgang ^b   Schnittger, Susanne ^b   Haferlach, Claudia ^b  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b MLL MUNICH LEUKEMIA LABORATORY   (Germany)

^c UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

Acute myelogenous leukemia, AML; Allogeneic hematopoietic stem cell transplantation (HSCT); Chromosome banding analysis; Clonal evolution; Relapse

Indexed keywords

ANTINEOPLASTIC AGENT;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RELAPSE; CHROMOSOME ABERRATION; CLONING; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOGENETICS; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; KARYOTYPE; MAJOR CLINICAL STUDY; MALE; RETROSPECTIVE STUDY;

ADULT; AGED; AGED, 80 AND OVER; CLONE CELLS; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; RECURRENCE; RETROSPECTIVE STUDIES; TRANSPLANTATION, HOMOLOGOUS; YOUNG ADULT;

EID: 78149407838     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2010.06.007     Document Type: Article

References (21)

1. Haferlach T., Bacher U., Haferlach C., Kern W., Schnittger S. Insight into the molecular pathogenesis of myeloid malignancies. Curr Opin Hematol 2007, 14:90-97.
2. Marcucci G., Mrozek K., Bloomfield C.D. Molecular heterogeneity and prognostic biomarkers in adults with acute myeloid leukemia and normal cytogenetics. Curr Opin Hematol 2005, 12:68-75.
3. Laane E., Derolf A.R., Bjorklund E., et al. The effect of allogeneic stem cell transplantation on outcome in younger acute myeloid leukemia patients with minimal residual disease detected by flow cytometry at the end of post-remission chemotherapy. Haematologica 2006, 91:833-836.
4. Schlenk R.F., Dohner K., Krauter J., et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 2008, 358:1909-1918.
5. Koreth J., Schlenk R., Kopecky K.J., et al. Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. JAMA 2009, 301:2349-2361.
6. Storb R. Can reduced-intensity allogeneic transplantation cure older adults with AML?. Best Pract Res Clin Haematol 2007, 20:85-90.
7. Kern W., Haferlach T., Schnittger S., et al. Karyotype instability between diagnosis and relapse in 117 patients with acute myeloid leukemia: implications for resistance against therapy. Leukemia 2002, 16:2084-2091.
8. Raghavan M., Smith L.L., Lillington D.M., et al. Segmental uniparental disomy is a commonly acquired genetic event in relapsed acute myeloid leukemia. Blood 2008, 112:814-821.
9. Kawamata N., Ogawa S., Seeger K., et al. Molecular allelokaryotyping of relapsed pediatric acute lymphoblastic leukemia. Int J Oncol 2009, 34:1603-1612.
10. Schmidt-Hieber M., Blau I.W., Richter G., et al. Cytogenetic studies in acute leukemia patients relapsing after allogeneic stem cell transplantation. Cancer Genet Cytogenet 2010, 198:135-143.
11. Bennett J.M., Catovsky D., Daniel M.T., et al. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol 1976, 33:451-458.
12. Bennett J.M., Catovsky D., Daniel M.T., et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med 1985, 103:620-625.
13. Schoch C., Schnittger S., Bursch S., et al. Comparison of chromosome banding analysis, interphase- and hypermetaphase-FISH, qualitative and quantitative PCR for diagnosis and for follow-up in chronic myeloid leukemia: a study on 350 cases. Leukemia 2002, 16:53-59.
14. Grimwade D., Hills R.K. Independent prognostic factors for AML outcome. Hematology Am Soc Hematol Educ Program 2009, 1:385-395.
15. Bacher U., Badbaran A., Fehse B., et al. Quantitative monitoring of NPM1 mutations provides a valid minimal residual disease parameter following allogeneic stem cell transplantation. J Exp Hematol 2009, 37:135-142.
16. Bader P., Klingebiel T., Schaudt A., et al. Prevention of relapse in pediatric patients with acute leukemias and MDS after allogeneic SCT by early immunotherapy initiated on the basis of increasing mixed chimerism: a single center experience of 12 children. Leukemia 1999, 13:2079-2086.
17. Schmid C., Labopin M., Nagler A., et al. Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukemia Working Party. J Clin Oncol 2007, 25:4938-4945.
18. Czibere A., Bruns I., Kroger N., et al. 5-Azacytidine for the treatment of patients with acute myeloid leukemia or myelodysplastic syndrome who relapse after allo-SCT: a retrospective analysis. Bone Marrow Transplant 2009, 45:872-876.
19. Chase A., Pickard J., Szydlo R., et al. Non-random involvement of chromosome 13 in patients with persistent or relapsed disease after bone-marrow transplantation for chronic myeloid leukemia. Genes chromosomes. Cancer 2000, 27:278-284.
20. Karrman K., Sallerfors B., Lenhoff S., Fioretos T., Johansson B. Cytogenetic evolution patterns in CML post-SCT. Bone Marrow Transplant 2007, 39:165-171.
21. Hiller B., Bradtke J., Balz H., Rieder H. CyDAS: a cytogenetic data analysis system. Bioinformatics 2005, 21:1282-1283.